154 related articles for article (PubMed ID: 37123466)
1. Imatinib Resistance in Chronic Myeloid Leukemia Associated with a D363G
Langabeer SE; Macleod S; Bhreathnach Ú; Fadalla K
Case Rep Hematol; 2023; 2023():6673144. PubMed ID: 37123466
[TBL] [Abstract][Full Text] [Related]
2. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
4. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
[TBL] [Abstract][Full Text] [Related]
5. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2022 Sep; 97(9):1236-1256. PubMed ID: 35751859
[TBL] [Abstract][Full Text] [Related]
6. Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations.
Ai J; Tiu RV
Ther Adv Hematol; 2014 Aug; 5(4):107-20. PubMed ID: 25360237
[TBL] [Abstract][Full Text] [Related]
7. BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia.
Amarante-Mendes GP; Rana A; Datoguia TS; Hamerschlak N; Brumatti G
Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057108
[TBL] [Abstract][Full Text] [Related]
8. New Developments in Chronic Myeloid Leukemia: Implications for Therapy.
Tabarestani S; Movafagh A
Iran J Cancer Prev; 2016 Feb; 9(1):e3961. PubMed ID: 27366312
[TBL] [Abstract][Full Text] [Related]
9. BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.
Quentmeier H; Eberth S; Romani J; Zaborski M; Drexler HG
J Hematol Oncol; 2011 Feb; 4():6. PubMed ID: 21299849
[TBL] [Abstract][Full Text] [Related]
10. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
[TBL] [Abstract][Full Text] [Related]
11. A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1
Gleixner KV; Sadovnik I; Schneeweiss M; Eisenwort G; Byrgazov K; Stefanzl G; Berger D; Herrmann H; Hadzijusufovic E; Lion T; Valent P
Leuk Res; 2019 Mar; 78():36-44. PubMed ID: 30711891
[TBL] [Abstract][Full Text] [Related]
12. A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Wagle M; Eiring AM; Wongchenko M; Lu S; Guan Y; Wang Y; Lackner M; Amler L; Hampton G; Deininger MW; O'Hare T; Yan Y
Leukemia; 2016 Jul; 30(7):1493-501. PubMed ID: 27044711
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells.
Tsubaki M; Takeda T; Matsuda T; Kimura A; Tanaka R; Nagayoshi S; Hoshida T; Tanabe K; Nishida S
BMB Rep; 2023 Feb; 56(2):78-83. PubMed ID: 36195570
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE
JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106
[TBL] [Abstract][Full Text] [Related]
15. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation of tyrosine kinase inhibitors based on
Kim Y; Kim S; Lee JM; Ahn A; Yoo JW; Lee JW; Cho B; Chung NG; Kim Y; Kim M
Front Pediatr; 2022; 10():928136. PubMed ID: 35967571
[TBL] [Abstract][Full Text] [Related]
17. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
Moore FR; Yang F; Press RD
Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
[TBL] [Abstract][Full Text] [Related]
18. Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations.
Razga F; Jurcek T; Zackova D; Dvorakova D; Toskova M; Jeziskova I; Mayer J; Racil Z
Mol Diagn Ther; 2012 Aug; 16(4):251-9. PubMed ID: 22873741
[TBL] [Abstract][Full Text] [Related]
19. Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid Leukemia.
Tadesse F; Asres G; Abubeker A; Gebremedhin A; Radich J
JCO Glob Oncol; 2021 Jul; 7():1187-1193. PubMed ID: 34292760
[TBL] [Abstract][Full Text] [Related]
20. Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor?
Valent P
Eur J Clin Invest; 2010 Oct; 40(10):918-31. PubMed ID: 20597967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]